Annexon, Inc. (ANNX)
Nasdaq · Healthcare · Biotechnology
$4.20+0.24%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $796M
- 52-week range
- $2.54 – $7.18
- 52-week change
- +31.76%
- EPS (trailing)
- −$1.13
- Analyst rating
- 1.6 Buy
- Next earnings
- Nov 9, 2026
Fiscal year to Dec 2025
- Net income
- −$207M
- Diluted EPS
- −$1.34
- Free cash flow
- −$187M
From the company’s annual report on SEC EDGAR.
About Annexon, Inc.
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Headquarters: Brisbane, United States · 92 employees · annexonbio.com